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Abstract
Background: SERPINE2, also known as glia-derived nexin or protease nexin-1, belongs to the serine protease
inhibitor (SERPIN) superfamily. It is one of the potent serpins that modulates the activity of the plasminogen
activator (PA) and was implicated in tissue remodeling. In this study, we investigated the expression patterns of
SERPINE2 in the mouse placenta and uterus during the estrous cycle, pregnancy, and lactation.
Methods: SERPINE2 was purified from mouse seminal vesicle secretion using liquid chromatography (LC) and
identified by LC/tandem mass spectrometry. The antiserum against the SERPINE2 protein was raised in rabbits. To
reveal the uterine and placental expression of SERPINE2, tissues at various stages were collected for real-time PCR
quantification, Western blotting, and immunohistochemical staining.
Results: Serpine2 mRNA was the major PA inhibitor in the placenta and uterus during the estrous cycle,
pregnancy, and lactation, although Serpine1 mRNA had higher expression levels than Serpine2 mRNA in the
placenta. Plat seemed to be the major PA in the mouse uterus and placenta. Antiserum against the SERPINE2
protein specifically recognized two forms of SERPINE2 and an extra 75-kDa protein, which was probably a
complex of SERPINE2 with a certain protease, from among thousands of protein components in the tissue
extract as demonstrated by Western blotting. In the uterus, SERPINE2 was primarily localized in luminal and
glandular epithelial cells but it also was detected in circular and longitudinal smooth muscle cells during the
estrous cycle and lactation. It was prominently expressed in decidual stroma cells, the metrial gland, and
endometrial epithelium of the pregnant uterus. In the placenta, SERPINE2 was expressed in trophoblasts of the
labyrinth and spongiotrophoblasts. However, its expression was remarkably reduced in giant cells which existed
in the giant cell-decidual junction zone. In contrast, prominent expression of SERPINE2 seemed to be detected
on clusters of glycogen cells near the junction zone. In addition, yolk sac membranes also showed high
expression of SERPINE2.
Conclusions: These findings indicate that SERPINE2 is a major PA inhibitor in the placenta and uterus during the
estrous cycle, pregnancy, and lactation. It may participate in the PA-modulated tissue remodeling process in the
mouse placenta and uterus.
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Background
The mammalian uterus undergoes drastic tissue remo-
deling during the estrous cycle, implantation, and preg-
nancy. Tissue remodeling requires a fine-tuned balance
between levels of proteases and their cognate inhibitors.
The plasminogen activator (PA) system refers to the PA
and its cognate inhibitors [1]. The PA is involved in tis-
sue remodeling by converting abundant extracellular
plasminogen into plasmin, an active protease, which
degrades the extracellular matrix. The classical substrate
of plasmin is fibrin, in fact, most other matrix proteins
can be cleaved by this enzyme [1]. So far, two forms of
PA, tissue-type (PLAT) and urokinase-type (PLAU) are
reported. The activity of PA is modulated by several
protease inhibitors that belong to the serine protease
inhibitor (SERPIN) superfamily, such as SERPINA5,
SERPINB2, SERPINE1, and SERPINE2 [2].
The PA system is associated with many physiological
processes, including ovulation, embryogenesis, and
embryo implantation in female reproductive tissues
[1,3], and pathological processes, such as neoplasia [1].
How SERPIN modulates the proteolytic activities of
PLAT/PLAU in reproductive tissue remodeling is of
great importance.
The expression and activity of PLAT and PLAU were
detected in female reproductive tissues, including the
endometrium during cycling [4,5], implantation [6], and
placentation [7-10]. Also, PLAU was found to be
expressed during mouse placental development [10].
SERPINE1 was demonstrated to be present in human
and mouse uteri during implantation [6,11], indicating
that the PA inhibitor is involved in implantation. It was
also detected in the placenta [8,9]. However, few studies
have examined uterine SERPINE2 expression. SER-
PINE2, also known as glia-derived nexin or protease
nexin-1, has broad anti-protease activity specific to ser-
ine proteases, including trypsin, thrombin, plasmin,
prostasin [12], and PLAU [13]. It is widely expressed in
various tissues [14]. Lin et al. reported that expression
levels of SERPINE2 in the monkey endometrium and
placenta during early pregnancy were weak or below the
level of detection [15]. On the contrary, SERPINE2 was
highly expressed in the human placenta throughout
pregnancy [16]. In rats, Serpine2 mRNA was exclusively
detected in endometrial stromal cells of the uterus, in
particular on day 6.5 postcoitally, thus suggesting that it
may be involved in the implantation process [17]. It
seems that different species have different expression
patterns for the Serpine2 gene. So far, no comprehensive
study has exactly determined the expression of SER-
PINE2 in the murine placenta and uterus during the
estrous cycle, pregnancy, and lactation. We therefore
conducted this investigation to reveal the placental and
uterine expression of the Serpine2 gene and the cellular
localization of SERPINE2 protein in mice.
Methods
Animals and tissue collection
Specific pathogen-free outbred ICR mice were bred and
maintained in the Animal Center of the Department of
Medical Research, Mackay Memorial Hospital. Animals
were treated according to institutional guidelines for the
care and use of experimental animals. They were housed
under controlled lighting (14 h of light, 10 h of dark) at
21~22°C and were provided with water and NIH-31
laboratory chow ad libitum. Normal 12-week-old adult
male mice were used to purify the SERPINE2 protein as
previously described [18]. The estrous cycle was staged
by examining vaginal smears as described by Rugh [19].
The vaginal impedance was monitored by the MK-10A
impedance checker (Muromachi Kikai, Tokyo, Japan) to
work as a reference prior to doing vagina smear. The
electric resistance of vagina has been used for determi-
nation of rat estrous cycle [20]. It also was useful for
mouse to monitor the distinct phase of estrous cycle.
The day when the vaginal plug was observed was desig-
nated day 0.5 of pregnancy. To investigate Serpine2
mRNA and protein expression in the placenta and
uterus at various physiological stages, adult non-preg-
nant and pregnant female mice were sacrificed and their
tissues removed. For each mouse, part of the tissue was
stored in liquid nitrogen for mRNA and protein ana-
lyses, and another part was fixed in 10% (v/v) formalde-
hyde for the immunohistochemical analysis.
RNA isolation, reverse transcription, and real-time
polymerase chain reaction (PCR)
Total RNA was extracted from tissue homogenates trea-
ted with DNase I using an RNeasy Mini kit (Qiagen,
Valencia, CA, USA). Five micrograms of total RNA was
then reverse-transcribed into a 20-μl first-strand com-
plementary (c)DNA pool using a High-Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions.
To examine Serpin gene expression, the real-time PCR
was conducted. PCR primers (Table 1) were designed to
cross the junction between the exon and intron. We
used the hypoxanthine guanine phosphoribosyltransfer-
ase (Hprt) gene as the internal loading control to nor-
malize the relative gene expression levels.
Samples (n = 4 or 5) at each stage were separately
analyzed. The PCR amplification efficiency for each
gene was tested to ensure that it was equivalent to that
of Hprt mRNA examined in a cDNA dilution series. The
PCR was performed in a total volume of 20 μl, contain-
ing 50 ng of tissue cDNA, 150 nM each of the forward
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and reverse primers, and 10 μl of 2× SYBR Green Mas-
ter Mix (Applied Biosystems). All reactions were per-
formed in triplicate and run on an ABI/PRISM 7500
Fast Sequence Detector System (Applied Biosystems)
under the following conditions: 50°C for 2 min, 95°C for
10 min, and then 40 cycles at 95°C for 15 s and 60°C
for 1 min. The threshold cycle (Ct) was defined as the
fractional cycle number at which the reporter fluores-
cence, i.e., the number of amplified copies, reached a
fixed threshold. A melting curve analysis was run to ver-
ify that only a single product had formed in the reac-
tion. The identity of the PCR products was confirmed
by DNA sequencing. Relative quantification of mRNA
expression was calculated by the 2-ΔΔCt method [21].
Protein purification and identification
To obtain the pure antigen to produce a highly specific
and sensitive antiserum, the native SERPINE2 protein
was purified from the mouse seminal vesicle secretion
(SVS), since the mouse seminal vesicle prominently
expresses SERPINE2 [14]. Adult male mice (10~12
weeks old) were sacrificed by cervical dislocation. The
SVS was collected, centrifuged, and fractionated succes-
sively by ion-exchange chromatography on a diethylami-
noethyl Sephacel (GE Healthcare Life Sciences,
Piscataway, NJ, USA) column and gel-filtered on a
Sephadex G-75 (GE Healthcare Life Sciences) column as
previously described [18]. Peak 2 eluted from the Sepha-
dex G-75 column was further subjected to ion-exchange
high-performance liquid chromatography (HPLC) on a
Protein PAK SP 5PW (Waters, Milford, MA, USA) col-
umn (7.5 cm × 7.5 mm). The column was eluted with a
linear gradient of 0%~60% (w/v) 1.0 M NaCl in 20 mM
sodium acetate at pH 6.0 at a flow rate of 1.0 ml/min
for 50 min. The chromatogram is shown in Additional
file 1, Figure S1. The protein concentration was deter-
mined using a bicinchoninic acid protein assay kit
(Pierce, Rockford, IL, USA). The purified protein was
identified by sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE) on a 15% gel slab (8.2 ×
7.3 × 0.075 cm). Protein bands on the SDS-PAGE gel
were excised and subjected to in-gel digestion with tryp-
sin following our previously described method [22]. The
result is shown in Additional file 1, Figure S1.
Production of the specific antiserum
Antisera against SERPINE2 were produced in New
Zealand white rabbits. The purified protein in normal
saline (0.4 mg/ml) was emulsified with Freund’s com-
plete adjuvant (1:1, v/v) (Sigma-Aldrich, St. Louis, MO,
USA). In total, 2 ml of the mixture was injected subcu-
taneously in multiple sites in a rabbit. Two rabbits were
Table 1 Summary of real-time PCR primers
Genea Primer Sequence Position Product size (bp)
Serpina5
Fb 5’-TCTCCATTGAGGCTACCTACAAACT-3’ 1071-1095
Rc 5’-GTGCACCATCTCAGACAACTTGA-3’ 1201-1179 131
Serpinb2
F 5’-TTCCGTGTGAACTCGCATGA-3’ 664-683
R 5’-GGAAGCAACAGGAGCATGCT-3’ 806-787 143
Serpine1
F 5’-CAGAGCAACAAGTTCAACTACACTGA-3’ 810-835
R 5’-CAGCGATGAACATGCTGAGG-3’ 915-896 106
Serpine2
F 5’-CAGATCATCAAGTCACGGCCT-3’ 269-289
R 5’-ACCGTGGAGAGCTGCTTCTTT-3’ 387-367 119
Plat
F 5’-AAGAGAGCAGCTCTGTTGGCAC-3’ 1366-1387
R 5’-AATGGAGACGATGCCTCATGC-3’ 1477-1457 112
Plau
F 5’-GAAGCGACCCTGGTGCTATG-3’ 445-464
R 5’-TTTGCTAAGAGAGCAGTCATGCA-3’ 526-504 82
Hprt
F 5’-GAATCACGTTTGTGTCATTAGTGAAA-3’ 752-777
R 5’-TGCGCTCATCTTAGGCTTTGTA-3’ 813-792 62
a GenBank accession nos.: Serpina5, NM_172953; Serpinb2, NM_011111; Serpine1, NM_008871; Serpine2, NM_009255; Plat, NM_008872; Plau, NM_008873; Hprt,
NM_013556.
b F, forward primer.
c R, reverse primer.
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boosted twice every 3 weeks with the mixture of the
same amount of purified protein and Freund’s incom-
plete adjuvant (1:1, v/v) (Sigma-Aldrich). Antiserum was
collected 10 days after the last injection.
Two hundred micrograms of the purified SERPINE2
protein was conjugated to AminoLink beads according
to the manufacturer’s instructions (Pierce). Antisera
against SERPINE2 were adsorbed by the conjugated
beads to remove the specific antibody against SER-
PINE2. The treated antiserum was used as the control
antiserum.
Western blotting
Tissue extract proteins were resolved using SDS-PAGE
on a 10% gel slab (8.2 × 7.3 × 0.075 cm) and were trans-
ferred to a nitrocellulose membrane for immunostaining
according to a previously described method [23]. Mem-
branes were blocked with 10% (w/v) skim milk in phos-
phate-buffered saline (PBS) (blocking solution) for 2 h,
and then incubated with anti-SERPINE2 antiserum (1:
5000) or monoclonal anti-a-tubulin (1: 15,000, Sigma-
Aldrich) in blocking solution for 1 h at room tempera-
ture. After gentle agitation in four changes of PBS for
15 min each, they were immunoreacted with horseradish
peroxidase (HRP)-conjugated goat anti-rabbit immuno-
globulin G (IgG) (1: 10,000, GE Healthcare Life
Sciences) or HRP-conjugated anti-mouse IgG (1: 15,000;
Cell Signaling Technology, Beverly, MA, USA) in block-
ing solution for 1 h. Immunoreactive bands were
revealed using an enhanced chemiluminescent (ECL)
substrate according to the manufacturer’s instructions
(Pierce).
Immunohistochemical staining
Tissues were collected, fixed in formalin, embedded in
paraffin, and cut into 5-μm sections. After the slides
were deparaffinized and hydrated, they were placed in a
plastic slide holder filled with the antigen retrieval AR-
10 solution (BioGenex, San Ramon, CA, USA), soaked
in a 70°C water bath, rapidly boiled to > 95°C, and
maintained for 15 min. While cooling to room tempera-
ture for 30 min, the slides were treated with 3% (v/v)
H2O2 in PBS for 15 min, blocked with 10% (v/v) normal
goat serum in PBS (blocking solution) for 1 h at room
temperature, and then incubated with anti-SERPINE2
antiserum or antiserum pretreated with SERPINE2-con-
jugated beads diluted 1: 700 in the blocking solution at
4°C for 16 h. After washing, the slides were treated with
biotin-conjugated goat anti-rabbit IgG (~3 μg/ml)
(Zymed Laboratories, South San Francisco, CA, USA) in
blocking solution for 1 h at room temperature. The
slides were washed again and then incubated with HRP-
conjugated streptavidin (~1 μg/ml) (Zymed Labora-
tories) in blocking solution for 40 min at room
temperature. Protein signals were detected by 3-amino-
9-ethylcarbazole staining (Zymed Laboratories). The
slides were then counterstained with hematoxylin (Vec-
tor Laboratories, Burlingame, CA, USA) and photo-
graphed using a Zeiss AxioImager Z1 microscope
system equipped with CCD camera and an automated
acquisition system (TissueGnostics, Vienna, Austria).
Statistical analysis
Data are presented as the mean ± standard deviation
(SD). Differences were analyzed by the one-way analysis
of variance (ANOVA) followed by Bonferroni post hoc
test using InStat software (GraphPad, San Diego, CA,
USA). A p value of < 0.05 was considered significant.
Results
Expression of the SERPINE2 protein in the mouse uterus
during the estrous cycle
We analyzed the gene expression of PAs and their cog-
nate inhibitors, i.e., Serpina5, Serpinb2, Serpine1, and
Serpine2, in the mouse uterus during the estrous cycle
by real-time PCR. As shown in Figure 1A, Plat mRNA
was apparently the most highly expressed PA in the
mouse uterus. Serpinea5 and Serpinb2 had very minor
signals or were not detected. However, Serpine2 mRNA
was the most prominently expressed PA inhibitor, while
Serpine1 mRNA was next. Serpine2 mRNA’s expression
was significant among PA inhibitors examined in the
cycling uterus, being especially prominent in metestrus
and diestrus uteri.
To produce specific antibodies, we purified the SER-
PINE2 protein from the SVS (see “Methods” and Addi-
tional file 1 for details) as the antigen. As revealed by
Western blotting, the antiserum against SERPINE2
recognized the purified 43-kDa band. Two forms, about
40- and 42-kDa bands, of SERPINE2 were detected
from thousands of protein components in the uterine
tissue extract collected from different phase of estrous
cycle (Figure 1B, arrows). An approximately 75-kDa
band was also seen at the four stages of the cycling
uterus (Figure 1B, arrowhead). The 75-kDa band was
probably the complex of SERPINE2 and its cognate pro-
tease, which were demonstrated in previous studies
[12,14,24,25]. Thus, two forms of SERPINE2 and an
extra 75-kDa SERPINE2-protease complex were
expressed in the mouse uterus. No signal was seen (data
not shown) when the antiserum was removed from the
blots and reprobed with the antiserum that was pre-
treated with SERPINE2-conjugated beads (control anti-
serum), indicating the high specificity of the antibody.
To reveal the cellular localization of the SERPINE2
protein in the mouse uterus during the estrous cycle, an
immunolocalization study was conducted using specific
anti-SERPINE2 antiserum. The SERPINE2 protein was
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primarily immunolocalized to luminal and glandular
epithelial cells and was weakly expressed in circular and
longitudinal smooth muscle cells at proestrus, estrus
and diestrus, but was nearly undetectable at metestrus.
Signals from stromal cells were relatively weaker (Figure
2A,B,E) except at metestrus (Figure 2D). However, when
slides were immunostained with control antiserum, no
signal was detected (Figure 2C).
Figure 1 Expression of the plasminogen activator (PA) and PA inhibitors in the mouse uterus during the estrus cycle. (A) Real-time PCR
was conducted to evaluate gene expression levels. Relative levels of mRNA were normalized to Hprt mRNA levels. Data are presented as the
mean of four individual experiments, and error bars represent the standard deviation (SD). a Significant difference compared to other Serpin
mRNA levels (p < 0.05). b Significant difference compared to Plau mRNA levels (p < 0.001). (B) Expression of the SERPINE2 protein in the cycling
uterus. Forty-five micrograms of total protein prepared from the homogenates of uterine tissue at proestrus (P, lane 2), estrus (E, lane 3),
metestrus (M, lane 4), and diestrus stages (D, lane 5) was analyzed by Western blotting. The purified SERPINE2 protein (30 ng) was loaded as the
positive control (lane 1). The arrowhead indicates a possible protein complex of SERPINE2 and a certain protease. Arrows indicate the isoform
proteins of SERPINE2. The a-tubulin protein level is shown as the loading control.
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Figure 2 Immunolocalization of SERPINE2 in the mouse uterus at different stages of the estrous cycle. Uterine sections during proestrus
(A), estrus (B, C), metestrus (D), and diestrus stages (E) were incubated with anti-SERPINE2 antiserum or the antiserum pretreated with SERPINE2
protein (control) (C), and then treated with biotin-conjugated goat-anti-rabbit IgG and horseradish peroxidase-conjugated streptavidin (red). For
contrast, specimens were further stained with hematoxylin (blue). Photographs were taken under bright-field illumination. Bar = 200 μm. cm,
circular muscle; ge, glandular epithelium; le, luminal epithelium; lm, longitudinal muscle; s, stroma.
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Expression of the SERPINE2 protein in the mouse uterus
and placenta during pregnancy
To assess the gene expression of PAs and PA inhibitors
in the pregnant uterus, a quantitative real-time PCR was
performed using several stages of uterine tissues during
pregnancy. As shown in Figure 3A, among the PA inhi-
bitors, Serpine2 mRNA seemed to be most highly
expressed in the pregnant uterus, while Plat and Plau
mRNA showed no differences in expression levels
among the different stages examined. The SERPINE2
protein was detected at various stages in the pregnant
uterus by Western blotting. The 75-kDa protein was
again detected in uterine tissues (Figure 3B). These
findings confirm the expression of Serpine2 mRNA and
protein in the gravid uterus.
Uterine expression of SERPINE2 was detected early in
the pregnancy of mice (Figure 4). On days 0.5 and 4.5,
SERPINE2 was primarily expressed in luminal and
glandular epithelia, while a visible protein signal was
also detected in the circular and longitudinal layers of
the myometrium (Figure 4AB). It should be noted that
stronger protein expression was found during the
implantation period on day 4.5 of pregnancy (Figure
4B). On day 5.5, SERPINE2 was prominently expressed
in stromal cells during decidualization (data not shown).
On day 7.5, trophoblast giant cells appeared among
Figure 3 Expression of Serpine2 mRNA and protein in the mouse uterus during pregnancy. (A) A real-time PCR analysis was conducted to
quantitate the Serpine2 gene’s expression levels at various pregnancy stages. The relative levels of mRNA were normalized to Hprt mRNA levels.
Data are presented as the mean ± standard deviation (SD) from four independent experiments. a Significant difference compared to other Serpin
mRNA levels (p < 0.05). (B) SERPINE2 protein expression in the uterus was examined at various pregnancy stages. Forty-five micrograms of total
protein prepared from various days of a pregnant uterus was analyzed by Western blotting. The arrowhead indicates a possible protein complex
of SERPINE2 and a certain protease. Arrows indicate the isoform proteins of SERPINE2. The a-tubulin protein level is shown as the loading
control.
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Figure 4 Immunolocalization of SERPINE2 in the mouse uterus during early pregnancy. Uterine sections prepared from a pregnant uterus
on days 0.5 (A), 4.5 (B), and 7.5 (C, D, and a-d) were histochemically stained as described in Figure 2. A control section stained with control
antiserum is shown (C). The black and white bars indicate 500 and 50 μm, respectively. amz, antimesometrial zone; cm, circular muscle; dec,
decidua; e, embryo; gc, giant cells; ge, glandular epithelium; le, luminal epithelium; lm, longitudinal muscle; mz, mesometrial zone.
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decidual stromal cells in the antimesometrial zone; how-
ever, their SERPINE2 protein expression was obviously
weaker (Figure 4D). Trophoblast giant cells that
stemmed from the embryo invaded decidual cells
(Figure 4D, a, b). Giant cells that appeared in the
antimesometrial zone showed significantly weaker SER-
PINE2 protein expression, while the situation was oppo-
site in the mesometrial zone (Figure 4D, c). In contrast
to the antimesometrial stroma, the mesometrial stroma
strongly expressed SERPINE2. In addition to prominent
Figure 5 Expression of Serpine2 mRNA and protein in the placenta. (A) Placental expression of Serpine2 mRNA. Quantitative real-time PCR
was conducted to analyze gene expression levels. The relative levels of mRNA were normalized to Hprt mRNA levels. Data are presented as the
mean of three individual experiments, and error bars represent the standard deviation (SD). a Significant difference compared to Serpine2 mRNA
levels (p < 0.001). b Significant difference compared to Plau mRNA levels (p < 0.001). (B) Placental SERPINE2 expression. Forty-five micrograms of
total protein prepared from the homogenates of placental tissue was analyzed by Western blotting. The arrowhead indicates a possible protein
complex of SERPINE2 and a certain protease. Arrows indicate the isoform proteins of SERPINE2. The a-tubulin protein level is shown as the
loading control.
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SERPINE2 expression in decidual cells, visible signals
were seen in the circular and longitudinal layers of the
myometrium (Figure 4D, d).
In the placenta, Plat mRNA seemed to be the most
highly expressed PA as demonstrated by a quantitative
real-time PCR (Figure 5A). Serpinea5 and Serpinb2
mRNAs were almost not detected, while Serpine1
mRNA was more highly expressed than was Serpine2
mRNA (Figure 5A). The SERPINE2 protein was
also detected in the placenta by Western blotting
(Figure 5B).
SERPINE2 was expressed in various cells in the pla-
centa and uterus during mid- and late-pregnancy. In the
uterus, it was prominently expressed in the decidua,
metrial gland, and endometrial epithelium and relatively
more weakly in the uterine myometrium on days 11.5,
13.5, and 17.5 of pregnancy (Figure 6). In the placenta,
the protein was localized in trophoblasts of the labyrinth
and spongiotrophoblasts. However, giant cells in the
junction zone showed significantly lower protein expres-
sion (Figure 6). It was interesting to note that high levels
of SERPINE2 were found in clusters of glycogen cells in
the junction region (Figure 6D,E,F). SERPINE2 was also
highly expressed on yolk sac membranes throughout the
pregnancy (Figure 6 and data not shown).
Expression of the SERPINE2 protein in the mouse uterus
during lactation
Serpine2 and Plat mRNAs had a tendency to be highly
expressed in the mouse uterus during lactation (Figure
7A). The SERPINE2 protein was consistently detected in
the postnatal uterus by Western blotting (Figure 7B).
Immunohistochemical staining showed that the SER-
PINE2 protein was strongly expressed in the luminal
epithelium in the uterus at postnatal days 1 and 2 (Fig-
ure 8B,C). Endometrial SERPINE2 expression was also
high even on postnatal day 14 (Figure 8D). The circular
and longitudinal layers of the myometrium had weak
SERPINE2 expression on postnatal days 1 and 2 in addi-
tion to the part around large vessels which had very
high SERPINE2 expression levels (Figure 8B,C). How-
ever, SERPINE2 expression in the longitudinal muscle
layer showed an increased signal on postnatal day 14
(Figure 8D).
Figure 6 Immunolocalization of SERPINE2 in the pregnant uterus and placenta on days 11.5, 13.5, and 17.5 of pregnancy. Uterine
sections were immunostained as described in Figure 2. Bars indicate 500 μm in A-C and 200 μm in D-I. cm, circular muscle; dec, decidua; e,
embryo; ee, endometrial epithelium; fv, fetal vessel; gc, giant cells; gly, glycogen cells; lb, labyrinth; lm, longitudinal muscle; mg, metrial gland;
mv, mother vessel; st, spongiotrophoblast; ysm, yolk sac membrane.
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Discussion
In this study, we demonstrated that SERPINE2 is one of
the major PA inhibitors that exists in the mouse pla-
centa and uterus, where it is extensively expressed in
various cell types. SERPINE2 is highly expressed in
decidual stroma cells during embryo implantation and
throughout placentation. It is expressed in labyrinthine
trophoblasts and spongiotrophoblasts in the placenta.
Intriguingly, giant cells expressed less SERPINE2 in the
junction zone, while a group of glycogen cells immedi-
ately near the giants cells prominently expressed
SERPINE2.
Giant cells in the mesometrial zone, which are differ-
entiated from cells of the ectoplacental cone [26,27], lar-
gely expressed SERPINE2, while giant cells’ SERPINE2
expression in the antimesometrial zone was low on day
7.5 of early pregnancy (Figure 4). Cells of the ectopla-
cental cone are precursors of the spongiotrophoblast
layer. Indeed, SERPINE2 was prominently expressed in
the spongiotrophoblast layer (Figure 6).
SERPINE2 can regulate the activity of serine proteases;
thus, it is most likely involved in tissue remodeling. Tis-
sue remodeling is an important biological event for
many reproductive processes occurred in the ovary,
uterus, and placenta, such as, follicle growth, ovulation,
estrous cycle, implantation, and placentation. SERPINE2
is previously demonstrated to be upregulated primarily
in dominant follicles during follicle growth [28,29] and
during ovulation [30]. However, relatively little work has
been done in the uterus. Although, in rats, Serpine2
mRNA is exclusively expressed in the endometrial
stroma and is upregulated at the time of implantation
[17], the Serpine2 mRNA and protein, in mice, is pri-
marily detected in the glandular and luminal cells and is
also upregulated at the implantation. The results suggest
a role for SERPINE2 in regulating tissue remodeling
during implantation.
The cell migration and invasion, the well-known events
during placentation, is tightly regulated by proteases and
their cognate protease inhibitors [27]. SERPINE2 is
widely expressed in various cell types throughout placen-
tation, indicating that this protein is involved in tissue
remodeling during placental development.
Our SERPINE2 antiserum detected two major SER-
PINE2 isoforms in the uterus and placenta. In a pro-
tein database search conducted with Basic Local
Alignment Search Tool (BLAST) algorithms (http://
www.ncbi.nlm.nih.gov/BLAST) against a non-redun-
dant database using the SERPINE2 protein sequence
(Swiss-Prot Q07235) as the query, three isoforms were
revealed with the accession numbers of gb|
EDL16269.1|, gb|EDL16267.1|, and gb|EDL16268.1|.
The theoretical molecular masses for the three iso-
forms were 30,812, 35,668, and 44,206 Da, respectively.
They are not processed by a signal peptidase. Thus,
the mature protein would have a smaller molecular
mass. However, the three proteins recognized by the
anti-SERPINE2 antiserum had larger molecular masses,
indicating they may be the glycosylated forms. In fact,
SERPINE2 was demonstrated to be expressed as two
glycoprotein forms [31]. Many alternatively spliced
gene products of SERPINE2 can also be seen on the
NCBI AceView website (http://www.ncbi.nlm.nih.gov/
IEB/Research/Acembly/). Previous reports also sup-
ported the existence of multiple forms of the SER-
PINE2 protein among mouse tissues [32].
Figure 7 Expression of Serpine2 mRNA and protein in the
uterus during lactation. (A) Expression of Serpine2 mRNA in the
postnatal uterus. Quantitative real-time PCR was conducted to
analyze gene expression levels. The relative levels of mRNA were
normalized to Hprt mRNA levels. Data are presented as the mean of
three individual experiments, and error bars represent the standard
deviation (SD). a Significant difference compared to other Serpin
mRNA levels (p < 0.001). b Significant difference compared to Plau
mRNA levels (p < 0.001). (B) Uterine SERPINE2 expression after birth.
Forty-five micrograms of total protein prepared from the
homogenates of uterine tissue was analyzed by Western blotting.
The arrowhead indicates a possible protein complex of SERPINE2
and a certain protease. Arrows indicate the isoform proteins of
SERPINE2. The a-tubulin protein level is shown as the loading
control. Pd1, postnatal day 1; Pd2, postnatal day 2; Pd14, postnatal
day 14.
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Previous studies demonstrated that SERPINE2 can
form a complex of approximately 75 kDa with PLAU
[14,24,25]. Also, SERPINE2 was shown to act as a suicide
inhibitor of prostasin through formation of an inactive
SDS-stable complex with it [12]. Thus, the 75-kDa band
detected by the anti-SERPINE2 antiserum may be the
complex of SERPINE2 and a certain protease. Prostasin
was detected in the monkey placenta [15]. Recently, pros-
tasin was demonstrated to have the ability to regulate
human placental trophoblast cell proliferation [33].
Although Serpine2 mRNA and the SERPINE2 protein
are highly expressed in the mouse placenta, Serpine1
mRNA seems to be the major PA inhibitor found there.
Similarly, SERPINE1 mRNA has higher expression levels
than those of SERPINE2 mRNA in the human placenta
throughout the three trimesters as demonstrated by
quantitative real-time PCR (our unpublished data). The
human SERPINE1 protein was intensely stained in tro-
phoblasts invading the decidua and myometrium and
was suggested to be a marker for invading trophoblasts
Figure 8 Immunolocalization of SERPINE2 in the uterus during lactation. Uterine sections were immunostained as described in Figure 2.
The uterus on postnatal day 1 stained with control antiserum is shown (A). Uteri on postnatal days 1 (B), 2 (C), and 14 (D) were stained with
anti-SERPINE2 antiserum. Bar = 500 μm. cm, circular muscle; ge, glandular epithelium; le, luminal epithelium; lm, longitudinal muscle.
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[34], while the human SERPINE2 protein was primarily
observed in the chorionic membrane and trophoblastic
epithelium [16].
In our study, we found that Serpinb2 mRNA was not
expressed or was below detection in the placenta and
uterus during pregnancy. However, the SERPINB2 pro-
tein is expressed in the human placenta [34,35]. SER-
PINB2 was detected in the cytoplasm of villous
syncytiotrophoblasts but not of villous cytotrophoblasts
or invading trophoblasts [34].
Our anti-SERPINE2 antibody was very sensitive in
detecting tissues in which there was trace expression of
SERPINE2, even better than the commercial antibody
which uses an Escherichia coli-expressed protein as the
immunogen (data not shown). Weak or very low levels
of SERPINE2 in the monkey endometrium and placenta
in a previous study [15] may have resulted from the fact
that they used the peptide or E. coli-expressed protein
as the immunogen which is often not in the native con-
formation of a protein. We used a purified native pro-
tein as the immunogen; thus, we had a more-specific
and -sensitive antiserum.
In an in situ hybridization study, rat Serpine2 mRNA
was found to be primarily localized in endometrial stro-
mal cells of the rat uterus [17]. We found that our anti-
SERPINE2 antibody could cross-react well to rat uterine
SERPINE2. Rat uterine SERPINE2 expression and locali-
zation were primarily in the endometrial epithelium,
similar to the mouse uterus during the estrous cycle
(Additional file 2, Figure S2). In fact, SERPINE2 was
also detected in the human uterine endometrium, myo-
metrium (our unpublished data), and placenta [16].
Thus, SERPINE2 must play some roles in uterine tissue
remodeling in the PA system, since SERPINE2 is the
major PA inhibitor in the uterus.
In conclusion, the SERPINE2 protein is the most
highly expressed PA inhibitor in the mouse uterus but
is second one in the placenta. The cellular localization
of SERPINE2 in the mouse placenta and uterus suggests
that SERPINE2 may play important roles in PA-modu-
lated tissue remodeling.
Additional material
Additional file 1: Supplemental Figure 1. Purification and identification
of SERPINE2 from the mouse seminal vesicle fluid.
Additional file 2: Supplemental Figure 2. Expression of the SERPINE2
protein in the rat uterus.
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